000			01509 a2200421 4500
005			20250512044647.0
264		0	_c19870724
008			198707s 0 0 eng d
022			_a0167-6997
024	7		_a10.1007/BF00207260 _2doi
040			_aNLM _beng _cNLM
100	1		_aOzer, H
245	0	0	_aCombination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma. _h[electronic resource]
260			_bInvestigational new drugs _c1987
300			_aS27-33 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnemia _xchemically induced
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aClinical Trials as Topic
650	0	4	_aCyclophosphamide _xadverse effects
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInterferon Type I _xadverse effects
650	0	4	_aLymphoma, Non-Hodgkin _xtherapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aThrombocytopenia _xchemically induced
700	1		_aAnderson, J R
700	1		_aPeterson, B A
700	1		_aBudman, D R
700	1		_aHenderson, E S
700	1		_aBloomfield, C D
700	1		_aGottlieb, A
773	0		_tInvestigational new drugs _gvol. 5 Suppl _gp. S27-33
856	4	0	_uhttps://doi.org/10.1007/BF00207260 _zAvailable from publisher's website
999			_c3303886 _d3303886